Compare Merck & Co., Inc. (MRK) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs TeraWulf Inc — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while TeraWulf Inc trades at $13.77 (market cap $6.81B). The key difference: Merck & Co., Inc. is far larger — about 51.6× TeraWulf Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and TeraWulf Inc for 17 Days on average.
| MRK | WULF | |
|---|---|---|
Market Cap | $351.28B | $6.81B |
Volume | 7,969,665 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $156.43 | $28.98 |
52-Week Low | $82.49 | $10.99 |
Typical Hold Time | 98 Days | 17 Days |
Enterprise Value | $398.04B | $9.43B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
WULF trades at $14.40, down 3.81% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The company reported a net loss of -$661.42M in 2025, with revenue of $168.46M, and has missed earnings expectations in recent quarters. Analyst consensus remains strongly bullish with a $34.92 price target, supported by positive news on AI data center leasing trends.
The outlook for WULF hinges on its pivot to AI data center hosting, offering growth potential, but significant risks persist from deep losses, negative margins, and high debt. Investors should weigh analyst optimism against fundamental weaknesses and volatile cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
